(Q53464291)

English

IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Mareki Ohtsuji

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Qingshun Lin

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Keiko Nishikawa

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Naomi Ohtsuji

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Hideki Okazaki

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Hiromichi Tsurui

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Hirofumi Amano

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Toshikazu Shirai

8

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Norihiro Nishimoto

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Hiroyuki Nishimura

10

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Sachiko Hirose

11

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

publication date

27 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Modern Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

25

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

270-277

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Osteoimmunology: interplay between the immune system and bone metabolism

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Osteoimmunology and the effects of the immune system on bone

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Cytokines in the pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Infliximab in active early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Severe inflammatory arthritis and lymphadenopathy in the absence of TNF.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Development of proteoglycan-induced arthritis is independent of IL-17.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Clinical value of blocking IL-6 receptor

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB x NZB) F(1) male mice: a new mouse model

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Monocyte and macrophage heterogeneity

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 production

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.950035

21 January 2018

Identifiers

10.3109/14397595.2014.950035

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/25159156

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53464291&oldid=1260396312"